Delays in the stroke thrombolysis pathway--identifying areas for improvement. by Brewer, Linda et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Geriatric and Stroke Medicine Articles Department of Geriatric and Stroke Medicine
1-5-2014
Delays in the stroke thrombolysis pathway--
identifying areas for improvement.
Linda Brewer
Royal College of Surgeons in Ireland, lindabrewer@rcsi.ie
Chinedum Arize
Royal College of Surgeons in Ireland
Joan McCormack
Royal College of Surgeons in Ireland
David Williams
Royal College of Surgeons in Ireland, davidwilliams@rcsi.ie
This Article is brought to you for free and open access by the Department
of Geriatric and Stroke Medicine at e-publications@RCSI. It has been
accepted for inclusion in Geriatric and Stroke Medicine Articles by an
authorized administrator of e-publications@RCSI. For more information,
please contact epubs@rcsi.ie.
Citation
Brewer L, Arize C, McCormack J, Williams D. Delays in the stroke thrombolysis pathway--identifying areas for improvement. Irish
Medical Journal. 2014;107(5):143-6.
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/gerstrmedart/3
  
Delays in the Stroke Thrombolysis Pathway - Identifying Areas for 
Improvement  
 
Linda Brewer,Chinedum Arize,Joan McCormack,David Williams 
Ir Med J. 2014 May;107(5):143-6 
L Brewer, C Arize, J McCormack, D Williams 
Beaumont Hospital, Beaumont, Dublin 9 
 
Abstract 
Despite international consensus on the benefits of thrombolysis for ischaemic stroke (IS), it 
remains underused. Guidelines now recommend a door-to-needle time of ≤60 minutes. We 
reviewed the rate and timeliness of thrombolysis for IS at our hospital. 323 stroke patients 
presented between January 2011 and April 2012.Thirty patients (10.6% of IS) were 
thrombolysed, mean age was 68.5 years (42 to 88) and 19 patients (63%) were male. 
Thirty-six patients (12.7% of IS) were not thrombolysed despite arriving within the time-
window and symptom resolution was the commonest reason (15 patients; 42%). Despite 
most thrombolysed patients (42%) presenting to the Emergency Department during 
daytime working hours, there were delays at each step of the acute care pathway. The 
mean time for stroke team review was 23 minutes (5-50). The mean door-to-CT and the 
door-to-needle times were 60 minutes (25-95) and 92 minutes (46-130) respectively. In 
parallel with national stroke incentives, local audit can highlight barriers to uptake and 
efficiency within thrombolysis services. 
  
Introduction 
It is now almost two decades since the effectiveness of thrombolytic therapy foracute IS was first reported. Results from the 
NINDS-rtPA trial in 1995,1 data from large randomized thrombolysis trials2 along with a Cochrane review,3 have supported 
the use of thrombolysis early in the acute IS setting. However, clinical outcomes are time dependent, with those receiving 
treatment more rapidly having better outcomes in the long and short-term. Pooled analysis of landmark trials reported that 
although patients benefited from treatment for up to 4.5h, there was a drop in the odds of a favourable outcome by a factor 
of two with each 90-minute period time delay.2 Every effort is therefore needed to avoid delays in starting treatment. 
 
Despite benefits, a limited proportion of eligible patients actually receive this treatment, with international reports 
documenting ongoing suboptimal rates(≤7%) even in well equipped centres.4-6 Delays in hospital presentation significantly 
contribute to this, but even when many IS patients are deemed eligible for thrombolysis, the actual rates of treatment can be 
relatively low.7,8Consequently, there is growing interest in highlighting in-hospital obstacles that contribute to low treatment 
rates and the fragmentation of what should be a well-organized pathway of care from arrival at the hospital door to 
administration of therapy. Guidelines recommend a door-to-needle target time of≤ 60 minutes,9,10 clearly requiring efficiency, 
including the rapid completion of clinical and imaging evaluation before initiating treatment in those without contra-
indications. Evidence from the Get with the Guidelines-Stroke national USregistry11 shows that less than one-third of acute IS 
patients who receive thrombolysis are actually treated within such guideline-recommended door-to-needle times. 
Consequently, the American Heart and Stroke Associations have launched ‘Target: Stroke Initiative’12 which includes multiple 
key best-practice strategies, and aims to achieve a door-to needle-time of ≤ 60minutes for at least 50% of IS patients. The 
effectiveness of implementing similar strategies has also been explored in Europe.13 
 
This study aimed to review the thrombolysis service at Beaumont Hospital (BH) from January 2011 to April 2012 inclusive. 
We reviewed the rate of thrombolysis and analysed the times taken for medical review, radiological investigation and 
administration of thrombolysis amongst those eligible to receive such therapy. Reasons for withholding treatment in those 




Beaumont is a 820-bed teaching hospital that provides emergency and acute care services to almost 300,000 people. The 
thrombolysis service is co-ordinated jointly by the Departments of Geriatric and Stroke Medicine and Neurology. A clear 
pathway of care outlines the steps that should be promptly undertaken from arrival of the patient with suspected stroke at 
the hospital, to imaging within the radiology department and administration of thrombolysis, where appropriate. In parallel, 
an education programme updates rotating medical staff within the ED and stroke service about this care pathway. The 
hospital stroke registry (for January 2011 to April 2012 inclusive) was reviewed. Two paper-based review proformas were 
designed for data collection: a ‘monthly proforma’ collected information on overall numbers of stroke patients that presented 
each month and a ‘thrombolysis’ proforma collected information on all thrombolysed patients during the study period. 
Patients' electronic records and charts were reviewed for any relevant data unavailable within the stroke registry and details 
of relevant radiological investigations were accessed through the McKesson system. 
Results 
323 stroke patients presented over a sixteen-month period from January 2011 to April 2012 inclusive (Figure 1). Overall, 
10.6% of all IS patients (30patients) received IV thrombolytic therapy during the study timeframe, although rates of 





     
 
Thrombolysed patients 
The mean age of this cohort was 68.5 years (range 42 to 88 years) and almost two-thirds (19 patients; 63%) were male. 
Baseline data are outlined in Table 1. Of the 30 thrombolysed patients, 4 patients had a suboptimal response and were 
considered for subsequent on-site intra-arterial (IA) thrombolysis and/orthrombectomy. Almost half (10; 42%) of those who 
presented after their stroke onset arrived between 9am and 5pm, with a further 9 patients (38%) presenting between 5pm 
and midnight. The remaining patients (20%) presented overnight (midnight to 9 am). Almost all (5/6) of the thrombolysed 
in-patient strokes received their treatment between 9am and 5pm. 
 
Timelines to administration of thrombolysis 
In cases where times were poorly documented within medical notes, nursing notes were reviewed. For patients who 
presented to the ED after their stroke onset, the mean time (from door) for a review by the stroke service was 23 minutes(5-
50). The mean door to CT time was 60 minutes (25-95) and the mean door to needle time was 92 minutes (46-130). For 
patients who had their stroke onset after admission to hospital, the mean time from symptom onset to review by the stroke 
service was 9 minutes (5-20). The mean time (from symptom onset) to CT was 42 minutes (15-90) and to needle was 99 





Haemorrhagic transformation (defined as any degree of haemorrhage seen radiologically) at 24hours post thrombolysis was 
noted in 6/30 patients (20%). However this rate decreased to 6.5% (2/30) when the presence of neurological worsening, as 
defined by the NINDS study,2 was incorporated into the definition. For thrombolysed patients, the mean number of days 
spent in the acute stroke unit was 19 (1-63) and the mean length of hospital stay was 44 days (2-164). Most patients were 
discharged to their own home (26;88%). The proportion of patients with a mRS of ≤2 was 3% at 7 days, 23% at 30 days 
and 37% at 90 days. The 7-day, 30-day and 90-day mortality was 6%, 13% and 16% respectively. 
 
Patients who presented within the 4.5h time-window and were not thrombolysed 
Of the 66 patients who presented within 4.5 hours, 36 patients (12.7% of all IS) were not thrombolysed due to a variety of 
reasons. The commonest reason was symptom resolution (15 patients; 42%). Other documented reasons for not 
administering thrombolysis were low NIHSS <4 (14%), patient on anticoagulation (dabigatran (2) or warfarin with INR≥2 




Our results show that, although most thrombolysed patients presented during full-service working hours, there was room for 
improved efficiency at each step in the acute thrombolysis care pathway. Only one-fifth of patients were thrombolysed within 
the target time-window of one hour and just over one-third were thrombolysed within 90 minutes of arrival at the door (or 
symptom onset for in-patient strokes). Delivery of thrombolysis took slightly longer amongst in-patients, possibly owing to 
reduced awareness of the urgency inactivating the stroke care pathway on the wards. In particular we found that there was 
scope to substantially decrease the proportion of time taken from stroke service review to CT and from CT to needle. During 
the study timeframe, thrombolysis was not commenced in the radiology department but instead the patient was transferred 
to another ward for administration of the thrombolysis bolus. Practice has since changed at our centre such that thrombolysis 
is now commenced in the radiology department. 
 
Although the thrombolysis rate at our hospital compares favourably with international standards, there is room for 
improvement. One striking finding was that just under one-quarter of patients in our cohort presented within the required 
time-window for consideration for thrombolytic treatment, similar to that reported in the Get with the Guidelines Stroke 
Program 2002 to 2009.14Heightened public awareness of stroke symptoms, and of the need to present urgently to 
emergency services can result in more prompt presentation of patients to emergency services.15,16 However, how campaigns 
are best delivered and whether they result in sustained improvements in thrombolysis rates remains unclear.17,18 The 
upgrading of emergency ambulance services can impact positively on time between symptom-onset to arrival 
athospital,19 although the co-ordination of ambulance services at a national level can be challenging. In Ireland the Health 
Service Executive National Stroke Program is currently working in partnership with national ambulance services to implement 
ambulance efficient access protocols for patients with ischaemic stroke. 
 
Studies assessing effective, multi-dimensional implementation strategies (education programmes, identification of treatment 
barriers and service goal-setting) have demonstrated improvements in administration rates and the efficiency of delivery of 
thrombolysis in IS. The PRACTISE trial13 implemented strategies to tackle under-utilisation of thrombolysis for IS. They 
identified obstacles to treatment as inter-organisational, intra-organisational, medical or psychological, against which they 
targeted intervention strategies. Patients in the intervention centres were more likely to receive thrombolysis (adjusted OR 
1.58; 95%CI 1.11-2.27) and a major component of this effect was the more appropriate local application of clear 
contraindications to treatment. However the intervention did not improve the timeliness of treatment administration. The 
INSTINCT study assessed whether a similar multilevel intervention could increase alteplase use in community hospitals in 
Michigan.20 Although the proportion of thrombolysed patients increased between the pre-intervention and post-intervention 
periods in intervention hospitals to a greater extent than the control hospitals, the difference was not significant(RR 1.37; 
95%CI 0.96-1.93; p=0.08). Authors identified barriers such as inter-departmental communication, familiarity with treatment 
guidelines and physician motivation as primary issues. 
 
Of those patients who presented to hospital within the 4.5 hour treatment-window, almost one-half (45%) were 
thrombolysed. The documented reasons for withholding treatment in the remaining patients were clear and in accordance 
with local and international guidance. The main reason for withholding treatment was symptom resolution, a contra-
indication that is clearly outlined in thrombolysis protocols. However, deterioration following spontaneous improvement can 
occur in up to 30% of certain subgroups.21 There is emerging evidence that treatment may be unnecessarily withheld in a 
substantial number of patients due to the application of strict thrombolytic exclusion criteria, many of which are not 
evidence-based. Studies now suggest that thrombolysis can be used safely in many excluded groups,22,23 including those with 
minor, fluctuating or resolving symptoms, advanced age or seizure at onset. Of patients in our study that had thrombolysis 
withheld due to symptom resolution, approximately three quarters had an acute infarct on imaging. As further evidence 
emerges and protocols are revised, perhaps more patients who arrive on time will be eligible for treatment. 
 
In Ireland, significant advances have been made in our stroke services (including thrombolysis rates) since the publication of 
the National Audit of Stroke Care in 2007. In conjunction with the launch of the National Stroke Program, the Stroke Register 
was established to collect information on the quality of care administered to stroke patients and this will help to identify 
areas where prioritised changes are necessary. Multiple guidelines, care bundles and pathways have been disseminated and 
service development has included the provision of telemedicine to enhance the co-ordination of thrombolysis services over 
large geographical areas. Stroke governance structures have also been enhanced with the development of local stroke teams 
and hospital networks and the appointment of clinical leaders. However, in parallel with such collaborative national 
incentives, local audit and focused initiatives must take place, which can result in significant reductions in time to CT 
andneedle.24,25 This would result in more favourable outcomes for many more patients with IS presenting to acute services. 
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